OBJECTIVE	To determine sirolimus steady-state pharmacokinetics , and to assess the relationship between time-normalized trough sirolimus concentration ( C ( min , TN ) ) and evidence of efficacy ( rejection and death ) and adverse reactions ( stomatitis and pneumonia ) in liver allograft patients .\